Recovery Peptides Ranked: BPC-157, TB-500, GHK-Cu, and Growth Hormone Secretagogues

Ranking recovery research compounds requires a multi-dimensional evaluation framework, because ‘best recovery peptide’ depends entirely on what tissue is being studied and what research question is being asked. A compound that is optimal for tendon repair research may be irrelevant to cardiac repair, and vice versa.

The framework used here evaluates five dimensions: (1) Evidence volume — how many published preclinical studies exist? (2) Evidence consistency — do independent groups replicate findings? (3) Human translational data — any Phase 1/2 human trial data? (4) Tissue specificity — which tissues have the strongest published evidence? (5) Mechanistic differentiation — is the mechanism unique, or redundant with other compounds?

This five-dimension ranking produces a different ordering than a simple ‘most studies’ approach and better reflects the research utility of each compound across different experimental designs. The ranking below covers the five recovery compounds most commonly studied in the peptide research literature: BPC-157, TB-500, GHK-Cu, and the GH secretagogue pair CJC-1295 + Ipamorelin.

The following table summarizes each compound across the evaluation dimensions, enabling researchers to match their compound selection to their specific research question.

For musculoskeletal recovery research: BPC-157 first, TB-500 second or co-administered. For cardiac repair: TB-500 leads, BPC-157 supportive. For skin and wound healing: GHK-Cu is the primary compound with human evidence. For systemic metabolic recovery: NAD+ has the most human data; CJC-1295/Ipamorelin for lean mass support.

BPC-157 (Body Protection Compound-157, a synthetic 15-amino acid fragment of a gastric mucosal protein) earns the top ranking on a single dimension that matters most for preclinical researchers: evidence volume and consistency. With over 500 published studies across more than three decades, from multiple independent research groups across multiple countries, BPC-157 has the largest and most internally consistent preclinical repair evidence base of any research peptide.

The evidence covers an exceptional range of tissue types. Musculoskeletal repair: published studies in Achilles tendon transection (Pevec et al., 2010), medial collateral ligament injury, quadriceps muscle tear, rotator cuff repair, and bone fracture models. GI repair: consistent effects in gastric ulcer, colitis (TNBS and DSS models), intestinal anastomosis, and fistula models. Neurological: documented effects in dopamine system, spinal cord injury, and peripheral nerve models. Cardiovascular: emerging literature on cardiac protection and vessel wall repair.

BPC-157's primary mechanism — promoting angiogenesis through eNOS upregulation and VEGF receptor sensitization — creates new blood vessel supply at injury sites, addressing the vascular component of tissue repair that is rate-limiting in avascular tissues (tendons, ligaments) and ischemic conditions. This mechanism is consistent across tissue types, which explains the breadth of BPC-157's preclinical evidence base.

Where BPC-157 ranks second: Human translational data. There are no published Phase 1 through 3 human clinical trials for BPC-157 as of mid-2026. This is a genuine limitation that TB-500 (parent protein Tβ4) and GHK-Cu do not share.

TB-500 ranks second overall but first on human translational data — the dimension that matters most when designing research with eventual clinical application in view. Its parent protein Thymosin Beta-4 (Tβ4) has completed Phase 2 clinical trials in three separate indications through RegeneRx Biopharmaceuticals, producing the most advanced human clinical dataset of any commonly studied repair peptide.

Published Phase 2 findings: The MOTIF trial (PMID 24042491) showed statistically significant improvements in myocardial viability by cardiac MRI in post-MI patients treated with IV Tβ4. Dry eye disease Phase 2b trial (PMID 29108011) showed statistically significant improvements in corneal staining with topical Tβ4 (RGN-259) versus placebo, progressing to Phase 3 ARISE trials. Peripheral artery disease Phase 1/2 showed favorable safety with preliminary efficacy signals on ankle-brachial index.

TB-500's primary mechanism — G-actin sequestration driving cell migration — is mechanistically complementary to BPC-157's angiogenesis mechanism. Where BPC-157 creates the blood vessel supply that healing tissue needs, TB-500 drives the directed cell migration (fibroblasts, keratinocytes, cardiomyocytes, endothelial cells) that populates and remodels the repair zone. This is why the BPC-157 + TB-500 combination is the most frequently studied pairing in preclinical repair research.

Secondary TB-500 mechanisms include NF-κB suppression (reducing pro-inflammatory cytokine production) and upregulation of angiogenic signals in ischemic tissue — providing additional overlap with BPC-157 in the vascular domain.

GHK-Cu ranks third overall but has a specific leadership position: it is the only recovery compound with published human randomized controlled trial data in a tissue repair context. Multiple peer-reviewed clinical trials in dermatology have demonstrated GHK-Cu effects on wound healing, skin thickness, wrinkle depth, and collagen synthesis in human subjects — providing a human evidence base that BPC-157 entirely lacks and that TB-500's clinical data (from disease populations, not general recovery) partially provides.

The Pickart & Margolina gene expression research (2018, *Frontiers in Aging Neuroscience*) identified over 4,000 human genes modulated by GHK-Cu, including upregulation of collagen synthesis genes, MMP inhibitors, antioxidant enzymes (SOD, catalase), DNA repair genes, and anti-inflammatory cytokines — while downregulating pro-inflammatory, pro-fibrotic, and senescence-associated genes. This breadth of gene regulation is mechanistically distinct from BPC-157 and TB-500, which act through more targeted receptor/cytoskeletal mechanisms.

For recovery research specifically, GHK-Cu's most relevant documented effects are: collagen I and III synthesis upregulation in fibroblast cultures, suppression of matrix metalloproteinases (MMP-1, MMP-2) that would otherwise degrade newly deposited matrix, acceleration of wound contraction and re-epithelialization, and improvement of tissue quality at healed wounds (scar architecture, tensile strength) relative to untreated controls.

GHK-Cu is most often used as a third agent in combination protocols — added to a BPC-157 + TB-500 base to provide the matrix quality and gene expression remodeling dimension that neither of the primary agents addresses.

CJC-1295 and Ipamorelin are ranked fourth because their mechanism addresses recovery indirectly rather than through direct tissue repair signaling. CJC-1295 is a GHRH (growth hormone-releasing hormone) analog that extends growth hormone pulse duration, while Ipamorelin is a ghrelin mimetic GH secretagogue that produces clean GH pulses without significant cortisol or prolactin co-stimulation. The combination produces supra-physiological GH release that drives downstream IGF-1 production.

The GH/IGF-1 axis contributes to recovery through several pathways: IGF-1 promotes satellite cell (muscle stem cell) activation for muscle repair, upregulates protein synthesis in muscle tissue, reduces fat oxidation substrate competition with protein, and has modest direct anabolic effects on connective tissue through IGF-1 receptor signaling. These effects support recovery from a metabolic and anabolic angle — providing the substrate environment in which direct repair mechanisms (BPC-157, TB-500, GHK-Cu) can operate more efficiently.

The distinction from the top three compounds is important: CJC-1295/Ipamorelin do not directly drive angiogenesis, cell migration, or collagen synthesis at injury sites. Their contribution is systemic and metabolic — improving the body's overall anabolic state, which indirectly supports repair. For researchers designing recovery protocols where metabolic state and lean mass are experimental variables, this combination is highly relevant. For researchers focused specifically on local tissue repair mechanisms, the top three compounds are more directly mechanistically appropriate.

Ipamorelin's regulatory context is notable: MK-677, a closely related orally active GH secretagogue with the same mechanism, has completed multiple Phase 2 and Phase 3 clinical trials (for growth hormone deficiency and muscle wasting in elderly populations), providing indirect human translational validation for the GH secretagogue mechanism class.

The most commonly cited combination in preclinical repair research — BPC-157 + TB-500 — reflects a mechanistic rationale that becomes clear when both mechanisms are understood together. Tissue repair requires two things simultaneously: a vascular supply to deliver oxygen, nutrients, and repair cells to the injury zone, and directed migration of those repair cells from the vasculature to the specific repair location.

BPC-157 addresses the first: by upregulating VEGF receptor expression on endothelial cells and promoting eNOS-derived NO, it drives angiogenesis and restores the blood supply that avascular or ischemic injured tissue lacks. Without adequate blood supply, even a full complement of repair cells cannot function efficiently.

TB-500 addresses the second: by sequestering G-actin in a form available for rapid F-actin polymerization, it drives the lamellipodia formation and directed cell migration that brings fibroblasts, keratinocytes, myoblasts, and endothelial cells from the vasculature into the repair zone. Cell migration velocity is the rate-limiting step in multiple repair models, and TB-500's primary mechanism directly accelerates this step.

The net effect of combining both: faster angiogenesis (BPC-157) delivers more repair cells to the injury zone, and faster cell migration (TB-500) deploys those cells into the repair tissue more efficiently. Published preclinical data in models where both compounds were tested shows that combination outcomes exceed either compound alone in several tissue types, consistent with this mechanistic rationale.

For researchers designing combination protocols, adding GHK-Cu to a BPC-157 + TB-500 base adds the matrix quality dimension: the newly formed granulation tissue (BPC-157 angiogenesis) populated by migrating cells (TB-500) is remodeled into higher-quality connective tissue (GHK-Cu gene expression) with better collagen I architecture, crosslinking, and MMP suppression.

The ranking above is useful for understanding relative evidence quality, but the optimal compound selection for any specific research project depends on the research question.

If studying tendon, ligament, or musculoskeletal repair: Start with BPC-157. It has the largest published evidence base in these specific tissue types and the most established protocols for rodent musculoskeletal injury models. Add TB-500 for combination studies.

If studying cardiac repair or ischemia: TB-500 leads. The MOTIF trial data and the substantial Tβ4 cardiac literature provide the strongest translational foundation for cardiac repair research. BPC-157 may be added for its angiogenic support.

If studying skin wound healing, collagen, or surface tissue: GHK-Cu leads, with the unique advantage of published human RCT data in this specific tissue context.

If studying GI repair or gut healing: BPC-157 is the primary compound with the most extensive GI-specific evidence. KPV may be added for inflammatory IBD models.

If studying systemic recovery and lean mass: CJC-1295 + Ipamorelin provides the GH/IGF-1 axis support relevant to this question, with NAD+ for the metabolic recovery dimension.

For comprehensive multi-tissue recovery: The BPC-157 + TB-500 + GHK-Cu combination addresses angiogenesis, cell migration, and matrix quality simultaneously — covering the primary mechanisms of tissue repair comprehensively.

All compounds described are research-use-only materials. None are approved for human therapeutic use. Researchers should consult primary published literature for dose and protocol selection specific to their model.